Market Trends Toward New Normal in Golden Ocean Group, Redhill Biopharma, Galapagos NV, Crawford, Amphastar Pharmaceuticals, and 51job — Emerging Consolidated Expectations, Analyst Ratings

NEW YORK, March 15, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Golden Ocean Group Limited (NASDAQ:GOGL), Redhill Biopharma Ltd. (NASDAQ:RDHL), Galapagos NV (NASDAQ:GLPG), Crawford & Company (NYSE:CRD.B), Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH), and 51job, Inc. (NASDAQ:JOBS), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

GOGL DOWNLOAD: http://Fundamental-Markets.com/register/?so=GOGL
RDHL DOWNLOAD: http://Fundamental-Markets.com/register/?so=RDHL
GLPG DOWNLOAD: http://Fundamental-Markets.com/register/?so=GLPG
CRD.B DOWNLOAD: http://Fundamental-Markets.com/register/?so=CRD.B
AMPH DOWNLOAD: http://Fundamental-Markets.com/register/?so=AMPH
JOBS DOWNLOAD: http://Fundamental-Markets.com/register/?so=JOBS

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Fundamental Markets, available for free download at the links above, examine Golden Ocean Group Limited (NASDAQ:GOGL), Redhill Biopharma Ltd. (NASDAQ:RDHL), Galapagos NV (NASDAQ:GLPG), Crawford & Company (NYSE:CRD.B), Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH), and 51job, Inc. (NASDAQ:JOBS) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

-----------------------------------------

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed March 13th, 2018. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

GOLDEN OCEAN GROUP LIMITED (GOGL) REPORT OVERVIEW

Golden Ocean Group's Recent Financial Performance

For the three months ended September 30th, 2017 vs September 30th, 2016, Golden Ocean Group reported revenue of $126.95MM vs $70.86MM (up 79.15%) and basic earnings per share $0.00 vs -$0.25. For the twelve months ended December 31st, 2016 vs December 31st, 2015, Golden Ocean Group reported revenue of $257.81MM vs $190.24MM (up 35.52%) and basic earnings per share -$1.34 vs -$7.30. Golden Ocean Group is expected to report earnings on May 23rd, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was -$0.17. The estimated EPS forecast for the next fiscal year is $0.54 and is expected to report on February 19th, 2019.

To read the full Golden Ocean Group Limited (GOGL) report, download it here: http://Fundamental-Markets.com/register/?so=GOGL

-----------------------------------------

REDHILL BIOPHARMA LTD. (RDHL) REPORT OVERVIEW

Redhill Biopharma's Recent Financial Performance

For the three months ended December 31st, 2017 vs December 31st, 2016, Redhill Biopharma reported revenue of $2.00MM vs $0.10MM (up 1,901.00%) and basic earnings per share -$1.11 vs -$1.10. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Redhill Biopharma reported revenue of $4.01MM vs $0.10MM (up 3,867.33%) and basic earnings per share -$2.58 vs -$2.29. Redhill Biopharma is expected to report earnings on May 2nd, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was -$0.50. The estimated EPS forecast for the next fiscal year is -$1.25 and is expected to report on February 28th, 2019.

To read the full Redhill Biopharma Ltd. (RDHL) report, download it here: http://Fundamental-Markets.com/register/?so=RDHL

-----------------------------------------

GALAPAGOS NV (GLPG) REPORT OVERVIEW

Galapagos NV's Recent Financial Performance

For the three months ended March 31st, 2017 vs March 31st, 2016, Galapagos NV reported revenue of $44.11MM vs $16.35MM (up 169.86%) and basic earnings per share -$0.32 vs $0.89. For the twelve months ended December 31st, 2016 vs December 31st, 2015, Galapagos NV reported revenue of $167.77MM vs $67.27MM (up 149.42%) and basic earnings per share $1.31 vs -$3.69. Galapagos NV is expected to report earnings on April 26th, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was -$0.31. The estimated EPS forecast for the next fiscal year is -$2.88 and is expected to report on February 28th, 2019.

To read the full Galapagos NV (GLPG) report, download it here: http://Fundamental-Markets.com/register/?so=GLPG

-----------------------------------------

CRAWFORD & COMPANY (CRD.B) REPORT OVERVIEW

Crawford's Recent Financial Performance

For the three months ended December 31st, 2017 vs December 31st, 2016, Crawford reported revenue of $313.54MM vs $293.62MM (up 6.78%) and basic earnings per share -$0.04 vs $0.13. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Crawford reported revenue of $1,163.71MM vs $1,177.59MM (down 1.18%) and basic earnings per share $0.49 vs $0.65 (down 24.62%). Crawford is expected to report earnings on May 14th, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was $0.13. The estimated EPS forecast for the next fiscal year is $0.95 and is expected to report on March 6th, 2019.

To read the full Crawford & Company (CRD.B) report, download it here: http://Fundamental-Markets.com/register/?so=CRD.B

-----------------------------------------

AMPHASTAR PHARMACEUTICALS, INC. (AMPH) REPORT OVERVIEW

Amphastar Pharmaceuticals' Recent Financial Performance

For the three months ended September 30th, 2017 vs September 30th, 2016, Amphastar Pharmaceuticals reported revenue of $57.92MM vs $64.22MM (down 9.82%) and basic earnings per share $0.00 vs $0.09. For the twelve months ended December 31st, 2016 vs December 31st, 2015, Amphastar Pharmaceuticals reported revenue of $255.17MM vs $251.52MM (up 1.45%) and basic earnings per share $0.23 vs -$0.06. Amphastar Pharmaceuticals is expected to report earnings on May 14th, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was $0.03. The estimated EPS forecast for the next fiscal year is $1.59 and is expected to report on March 11th, 2019.

To read the full Amphastar Pharmaceuticals, Inc. (AMPH) report, download it here: http://Fundamental-Markets.com/register/?so=AMPH

-----------------------------------------

51JOB, INC. (JOBS) REPORT OVERVIEW

51job's Recent Financial Performance

For the three months ended September 30th, 2017 vs September 30th, 2016, 51job reported revenue of $108.27MM vs $88.37MM (up 22.52%) and basic earnings per share -$0.41 vs $0.28. For the twelve months ended December 31st, 2016 vs December 31st, 2015, 51job reported revenue of $336.79MM vs $317.27MM (up 6.15%) and basic earnings per share $1.40 vs $1.65 (down 15.15%). 51job is expected to report earnings on May 3rd, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was $0.45.

To read the full 51job, Inc. (JOBS) report, download it here: http://Fundamental-Markets.com/register/?so=JOBS

-----------------------------------------

ABOUT FUNDAMENTAL MARKETS

Fundamental Markets serves thousands of members and have provided research through some of the world's leading brokerages for over a decade–and continue to be one of the best information sources for investors and investment professionals worldwide. Fundamental Markets' roster boasts decades of financial experience and includes top financial writers, FINRA® BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst® (CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.

REGISTERED MEMBER STATUS

Fundamental Markets' oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Fundamental Markets' roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Fundamental Markets' Compliance department by Phone, at +1 667-401-0010, or by E-mail at [email protected].

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact:
Andrew Duffie, Media Department
Office: +1 667-401-0010
E-mail: [email protected]

© 2018 Fundamental Markets. All Rights Reserved. For republishing permissions, please contact a partner network manager at [email protected].

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.